Clinical Trials Logo

Clinical Trial Summary

The goal of the prospective, interventional, self-control, open, single-center clinical study: is to evaluate the value of the delayed ductal imaging of contrast enhanced Spectral Mammography acquired in 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography for the clinical diagnosis of patients with suspected pathologic nipple discharge. The main questions aim to answer are: 1. Percentage of changes from baseline in imaging diagnosis caused by the results of delayed imaging. 2. The rate of reported examination-related adverse events occurred within 7 days of the delayed ductal imaging. 3. The average gland dose (AGD) of delayed ductal imaging. After enrollment, subjects underwent CESM again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing.


Clinical Trial Description

As an exploratory study, the study plans to conduct another imaging using contrast-enhanced spectral mammography (CESM) 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography, so as to explore the optimization of the ductography technique and attempt to make a systematic description of the mammary duct structure in the Chinese population of patients with pathological nipple discharge, and thus to assess the clinical value of this delayed imaging protocol, including the effectiveness of the diagnostic dimension of the disease and the safety of the radiation dose and the degree of patient tolerance. ;


Study Design


NCT number NCT06033573
Study type Interventional
Source Wuhan Union Hospital, China
Contact Fan Yang, Dr.
Phone 008685726114
Email fyang@vip.163.com
Status Recruiting
Phase N/A
Start date August 1, 2023
Completion date August 1, 2024